Nearly one billion individuals worldwide suffer from obstructive sleep apnea (OSA) and are potentially impacted by related neurodegeneration. TFEB is considered a master regulator of autophagy and lysosomal biogenesis, but little is known about its role in neuronal oxidative stress and resultant injury induced by OSA. This study aimed to investigate these issues. Here, we demonstrated that neuronal TFEB induction is repressed in OSA mouse models. Activation of a TFEB-dependent autophagy-lysosomal pathway (ALP) reduces hippocampal neuronal cell death and mitigates OSA-related cognitive impairment. Neuronal NRF2 induction was also found to be defective in OSA mouse models. A series of staining assays for HO1, SOD3, ROS, GSH, 8-OHdG, MDA and PI revealed that enhancement of NRF2 expression restores neuronal redox balance and protects hippocampal neurons. We then identified a novel interplay between TFEB-dependent ALP and NRF2-mediated relief of oxidative stress. Inhibition of NRF2 hinders TFEB expression and lysosomal biogenesis. Conversely, knockdown of TFEB or blocking autophagy dampens the antioxidative effect of NRF2. Our findings highlight the unexpected and crucial role of TFEB-dependent ALP as a downstream event of NRF2 in NRF2-promoted redox balance. This study provides novel insights into the mechanism behind NRF2-driven antioxidative action and the regulation of TFEB-dependent ALP.
Obstructive sleep apnea (OSA) is increasingly recognized for its link to idiopathic pulmonary fibrosis (IPF), though the underlying mechanisms remain poorly understood. Histone lysine demethylase 6B (KDM6B) may either prevent or promote organ fibrosis, but its specific role in IPF is yet to be clarified. This study aimed to investigate the function and mechanisms of KDM6B in IPF and the exacerbating effects of OSA. We assessed KDM6B levels in lung tissues from IPF patients, IPF mouse models, and a dual‐hit model combining OSA‐associated intermittent hypoxia (IH) with bleomycin (BLM) or TGF‐β1. We evaluated pulmonary fibrosis, myofibroblast activation, and oxidative stress. KDM6B levels were elevated in lung tissues from IPF patients and BLM‐treated mice, as well as in TGF‐β1‐stimulated myofibroblasts. Importantly, IH significantly worsened BLM‐induced pulmonary fibrosis and TGF‐β1‐induced myofibroblast activation, further amplifying KDM6B expression both in vivo and in vitro. Inhibition of KDM6B reduced pulmonary fibrosis and decreased fibroblast activation and migration in IPF and dual‐hit models. Mechanistically, KDM6B inhibition led to decreased NOX4 expression and reduced oxidative stress. KDM6B plays a critical role in promoting pulmonary fibrosis and mediating the exacerbating effects of OSA on this condition. Our findings identify KDM6B as a novel potential therapeutic target for IPF.
Background and Objective: Idiopathic pulmonary fibrosis is a progressive interstitial lung disease characterised by excessive activation of myofibroblasts. However, currently available antifibrotic drugs exhibit limited efficacy. The dysregulation of redox processes plays a significant role in the pathogenesis of idiopathic pulmonary fibrosis. Dextromethorphan (DM) is used in the treatment of various inflammation‐related diseases. This study aimed to investigate the effectiveness of the combination of DM and pirfenidone (PFD) in treating idiopathic pulmonary fibrosis in both animal models and humans.Methods: In a bleomycin‐induced pulmonary fibrosis mouse model, the anti‐fibrotic effects of DM and/or PFD were assessed by evaluating fibrotic area, hydroxyproline levels, and fibrotic markers. In a transforming growth factor‐β1‐induced cell model, proliferation, migration, fibrosis markers, and oxidative stress were analysed to elucidate the mechanisms underlying the anti‐fibrotic actions of DM and/or PFD. Finally, the efficacy of DM combined with PFD in patients with pulmonary fibrosis was evaluated by comparing pulmonary imaging scores and pulmonary function before and after treatment in the PFD group and the PFD + DM group.Results: We observed that even ultralow doses of DM, either alone or in combination with PFD, demonstrated substantial protective effects in mice. Notably, administration of DM or combined drugs at 2 weeks after bleomycin modelling still showed anti‐fibrotic effects. In vitro, DM monotherapy and combination therapy restored the redox balance by suppressing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4/reactive oxygen species production and upregulating superoxide dismutase, contributing to their anti‐fibrotic mechanisms. In the clinical study, add‐on DM improved PFD in mitigating pulmonary function decline and improving chest high‐resolution computed tomography imaging scores.Conclusions: Ultralow doses of dextromethorphan significantly alleviate pulmonary fibrosis in bleomycin‐treated mice through restoring the redox balance. Add‐on DM improves the effects of PFD in both bleomycin‐treated mice and patients with pulmonary fibrosis.Trial Registration: ChiCTR2000037602
Background: Lung cancer is a leading cause of cancer-related deaths around the world, but its impact on young and middle-aged individuals (aged 15–45 years) is less understood. The aim of this study was to assess the global burden of lung cancer in those aged 15–45 years during 1990–2021.Methods: This study estimated global trends in prevalence, mortality, and disability-adjusted life years (DALYs) associated with lung cancer in this age group. The Global Burden of Disease Study 2021 was utilized to analyze data from 1990 to 2021. We examined variations by sex, age subgroup, sociodemographic index (SDI), and region and assessed key risk factors contributing to DALYs.Results: Our findings reveal that while the number of lung cancer cases aged 15–45 increased by 22.1%, the age-standardized prevalence decreased by 23.9%; age-standardized mortality and DALYs declined significantly over the past three decades. The decrease was more evident among men than women, despite men having a higher overall disease burden. In high-SDI countries, prevalence and DALYs experienced substantial decreases, whereas low-SDI countries experienced increases, particularly among women. East Asia demonstrated a high disease burden. Smoking was identified as the most prominent risk factor, especially in high-middle SDI countries. Household air pollution and ambient particulate matter pollution came after it.Conclusion: The study underscores the effectiveness of tobacco control measures and early screening in reducing lung cancer burden among young and middle-aged individuals. Nevertheless, the upward trends in low - SDI countries emphasize the necessity for interventions that are specifically aimed at environmental risk factors and smoking cessation initiatives. These findings provide valuable insights for policymakers and healthcare providers aiming to implement strategies to further cut down the global burden of lung cancer in the younger population.
The persistent global spread of HIV and drug-resistant tuberculosis (HIV/DR-TB) co-infection poses a significant challenge to international tuberculosis control efforts. This study aimed to analyze the global burden of HIV/DR-TB co-infection across age groups, genders, and Socio-demographic Index (SDI) regions, while identifying attributable risk factors. Data from the Global Burden of Disease (GBD) 2021 and joinpoint regression analysis were utilized to examine epidemiological trends from 1990 to 2021 across different genders and SDI regions. The Bayesian Age-Period-Cohort (BAPC) model was employed to forecast trends up to 2031. HIV and multidrug-resistant tuberculosis (HIV/MDR-TB) co-infection exhibited no significant gender differences in prevalence, incidence, mortality, or DALYs (P = 0.053, 0.277, 0.354, 0.212). In contrast, HIV and extensively drug-resistant tuberculosis (HIV/XDR-TB) co-infection showed significantly higher rates in males for all outcomes (P = 0.007, 0.003, 0.003, 0.005). Burden distribution varied by SDI quintile: Low SDI bore a greater HIV/MDR-TB co-infection burden. High-middle SDI had higher HIV/XDR-TB co-infection prevalence. Unsafe sex was the predominant risk factor for HIV/DR-TB co-infections in both genders, followed by drug use in males and intimate partner violence in females. Regional risk patterns revealed that male drug use was more strongly associated with HIV/DR-TB co-infection in high-middle SDI regions, whereas unsafe sex and intimate partner violence (in females) showed greater impact in low SDI regions. Projections indicated a steady decline in HIV/DR-TB co-infection from 2021 to 2031. Despite observed declines, HIV/DR-TB co-infection continues to pose a significant public health challenge. Regional SDI-stratified interventions are urgently needed: low-SDI settings should prioritize healthcare system strengthening to address gender-specific vulnerabilities including unsafe sexual practices and intimate partner violence, while high-middle SDI regions require comprehensive drug abuse prevention programs combining public education with enhanced pharmaceutical controls.